{"pmid":32482888,"title":"Cellular pathology in the COVID-19 era: a European perspective on maintaining quality and safety.","text":["Cellular pathology in the COVID-19 era: a European perspective on maintaining quality and safety.","COVID-19 is a zoonotic viral infection that originated in Wuhan, China, in late 2019. WHO classified the resulting pandemic as a 'global health emergency' due to its virulence and propensity to cause acute respiratory distress syndrome. The COVID-19 pandemic has had a major impact on diagnostic laboratories, particularly those handling cell and tissue specimens. This development carries serious implications for laboratory practice in that safety of personnel has to be balanced against high-quality analysis and timely reporting of results. The aim of this article is to present some recommendations for the handling of such specimens in the preanalytical, analytical and postanalytical phases of laboratory testing and analysis in an era of high COVID-19 prevalence, such as that seen, for example, in the UK, Spain, Italy and France.","J Clin Pathol","Gosney, John R","Hofman, Paul","Troncone, Giancarlo","Lopez-Rios, Fernando","32482888"],"abstract":["COVID-19 is a zoonotic viral infection that originated in Wuhan, China, in late 2019. WHO classified the resulting pandemic as a 'global health emergency' due to its virulence and propensity to cause acute respiratory distress syndrome. The COVID-19 pandemic has had a major impact on diagnostic laboratories, particularly those handling cell and tissue specimens. This development carries serious implications for laboratory practice in that safety of personnel has to be balanced against high-quality analysis and timely reporting of results. The aim of this article is to present some recommendations for the handling of such specimens in the preanalytical, analytical and postanalytical phases of laboratory testing and analysis in an era of high COVID-19 prevalence, such as that seen, for example, in the UK, Spain, Italy and France."],"journal":"J Clin Pathol","authors":["Gosney, John R","Hofman, Paul","Troncone, Giancarlo","Lopez-Rios, Fernando"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482888","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/jclinpath-2020-206789","keywords":["decontamination","laboratory personnel","safety"],"locations":["Wuhan","China","GBR","Spain","Italy","France"],"countries":["United Kingdom","Italy","France","Spain","China"],"countries_codes":["GBR|United Kingdom","ITA|Italy","FRA|France","ESP|Spain","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668704334402027520,"score":9.490897,"similar":[{"pmid":32198190,"title":"Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore.","text":["Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore.","The coronavirus disease 2019 (COVID-19) is a zoonotic viral infection originating from Wuhan, China in December 2019. The World Health Organization has classified this pandemic as a global health emergency due to its virulent nature of transmission, which may lead to acute respiratory distress syndrome. Singapore's health ministry has responded with enhanced surveillance of COVID-19 for all suspected pneumonia cases, further increasing the volume of testing via real-time reverse transcription PCR, as well as samples necessitating stringent infectious control. Collectively, this has implications on the total testing process, laboratory operations and its personnel due to biosafety concerns. Turnaround time for routine testing may also be affected. The aim of this article is to present our tertiary institution's early experience with managing this emerging crisis and offer practical considerations for the preanalytical, analytical and postanalytical phases of laboratory testing in this cohort of patients.","J Clin Pathol","Tan, Shaun S","Yan, Benedict","Saw, Sharon","Lee, Chun Kiat","Chong, Ai Teng","Jureen, Roland","Sethi, Sunil","32198190"],"abstract":["The coronavirus disease 2019 (COVID-19) is a zoonotic viral infection originating from Wuhan, China in December 2019. The World Health Organization has classified this pandemic as a global health emergency due to its virulent nature of transmission, which may lead to acute respiratory distress syndrome. Singapore's health ministry has responded with enhanced surveillance of COVID-19 for all suspected pneumonia cases, further increasing the volume of testing via real-time reverse transcription PCR, as well as samples necessitating stringent infectious control. Collectively, this has implications on the total testing process, laboratory operations and its personnel due to biosafety concerns. Turnaround time for routine testing may also be affected. The aim of this article is to present our tertiary institution's early experience with managing this emerging crisis and offer practical considerations for the preanalytical, analytical and postanalytical phases of laboratory testing in this cohort of patients."],"journal":"J Clin Pathol","authors":["Tan, Shaun S","Yan, Benedict","Saw, Sharon","Lee, Chun Kiat","Chong, Ai Teng","Jureen, Roland","Sethi, Sunil"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198190","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1136/jclinpath-2020-206563","keywords":["chemical pathology","chemistry","infection control","laboratory management"],"locations":["Wuhan","China","Singapore","Singapore"],"countries":["China","Singapore"],"countries_codes":["CHN|China","SGP|Singapore"],"topics":["Prevention"],"weight":1,"_version_":1666138490090291201,"score":290.5163},{"pmid":32172228,"title":"Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","text":["Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance.","Clin Chem Lab Med","Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario","32172228"],"abstract":["A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32172228","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0285","keywords":["covid-19","coronavirus","diagnosis","reverse transcription polymerase chain reaction (rt-pcr)"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492600582146,"score":178.23569},{"pmid":32245835,"title":"The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges.","text":["The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges.","The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by SARS-CoV-2. In the pre-analytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time RT-PCR assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak.","J Clin Microbiol","Tang, Yi-Wei","Schmitz, Jonathan E","Persing, David H","Stratton, Charles W","32245835"],"abstract":["The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by SARS-CoV-2. In the pre-analytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time RT-PCR assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak."],"journal":"J Clin Microbiol","authors":["Tang, Yi-Wei","Schmitz, Jonathan E","Persing, David H","Stratton, Charles W"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245835","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1128/JCM.00512-20","topics":["Diagnosis"],"weight":1,"_version_":1666138492035399681,"score":144.732},{"pmid":32434770,"title":"Predictive molecular pathology in the time of COVID-19.","text":["Predictive molecular pathology in the time of COVID-19.","AIMS: In the time of COVID-19, predictive molecular pathology laboratories must still timely select oncological patients for targeted treatments. However, the need to respect social distancing measures may delay results generated by laboratory-developed tests based on sequential steps a long hands-on time. Laboratory workflows should now be simplified. METHODS: The organisation of the University of Naples Federico II predictive pathology laboratory was assessed before (March-April 2019) and during (March-April 2020) the Italian lockdown. RESULTS: The number of patients undergoing single or multiple biomarker testing was similar in 2019 (n=43) and in 2020 (n=45). Considering adequate samples for molecular testing, before the outbreak, next-generation sequencing was mostly used (35/42, 83.3%). Testing six genes had a reagent cost of euro98/patient. Conversely, in 2020, almost all cases (38/41, 92.7%) were analysed by automated testing. This latter had for any single assay/gene a significant reagent cost (euro95-euro136) and a faster mean turnaround time (5.3 vs 7.9 working days). CONCLUSION: In the times of coronavirus, laboratory fully automated platforms simplify predictive molecular testing. Laboratory staff may be more safely and cost-effectively managed.","J Clin Pathol","Malapelle, Umberto","De Luca, Caterina","Iaccarino, Antonino","Pepe, Francesco","Pisapia, Pasquale","Russo, Maria","Sgariglia, Roberta","Nacchio, Mariantonia","Vigliar, Elena","Bellevicine, Claudio","Schmitt, Fernando C","Troncone, Giancarlo","32434770"],"abstract":["AIMS: In the time of COVID-19, predictive molecular pathology laboratories must still timely select oncological patients for targeted treatments. However, the need to respect social distancing measures may delay results generated by laboratory-developed tests based on sequential steps a long hands-on time. Laboratory workflows should now be simplified. METHODS: The organisation of the University of Naples Federico II predictive pathology laboratory was assessed before (March-April 2019) and during (March-April 2020) the Italian lockdown. RESULTS: The number of patients undergoing single or multiple biomarker testing was similar in 2019 (n=43) and in 2020 (n=45). Considering adequate samples for molecular testing, before the outbreak, next-generation sequencing was mostly used (35/42, 83.3%). Testing six genes had a reagent cost of euro98/patient. Conversely, in 2020, almost all cases (38/41, 92.7%) were analysed by automated testing. This latter had for any single assay/gene a significant reagent cost (euro95-euro136) and a faster mean turnaround time (5.3 vs 7.9 working days). CONCLUSION: In the times of coronavirus, laboratory fully automated platforms simplify predictive molecular testing. Laboratory staff may be more safely and cost-effectively managed."],"journal":"J Clin Pathol","authors":["Malapelle, Umberto","De Luca, Caterina","Iaccarino, Antonino","Pepe, Francesco","Pisapia, Pasquale","Russo, Maria","Sgariglia, Roberta","Nacchio, Mariantonia","Vigliar, Elena","Bellevicine, Claudio","Schmitt, Fernando C","Troncone, Giancarlo"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434770","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jclinpath-2020-206711","keywords":["laboratory personnel","medical oncology","pathology, molecular"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1667521393637457923,"score":142.35988},{"pmid":32502333,"title":"Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens.","text":["Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens.","SARS-CoV-2 is a novel coronavirus that causes the acute respiratory disease-Coronavirus disease 2019 (COVID-19)-which has led to a global health crisis. Currently, no prophylactics or therapies exist to control virus spread or mitigate the disease. Thus, the risk of infection for physicians and scientists is high, requiring work to be conducted in Biosafety Level-3 (BSL-3) facilities if virus will be isolated or propagated. However, inactivation of the virus can enable safe handling at a reduced biosafety level, making samples accessible to a diverse array of institutions and investigators. Institutions of all types have an immediate need for guidelines that outline safe collection, handling, and inactivation of samples suspected to contain active virus. Here we provide a practical guide for physicians and researchers wishing to work with materials from patients who are COVID-19 positive or suspected positive. (c) 2020 Wiley Periodicals LLC. Basic Protocol 1: Practical guidelines for the safe collection and handling of specimens collected from COVID-19 and suspected COVID-19 patients Basic Protocol 2: Inactivating SARS-CoV-2.","Curr Protoc Cytom","Bain, William","Lee, Janet S","Watson, Alan M","Stitt-Fischer, Molly S","32502333"],"abstract":["SARS-CoV-2 is a novel coronavirus that causes the acute respiratory disease-Coronavirus disease 2019 (COVID-19)-which has led to a global health crisis. Currently, no prophylactics or therapies exist to control virus spread or mitigate the disease. Thus, the risk of infection for physicians and scientists is high, requiring work to be conducted in Biosafety Level-3 (BSL-3) facilities if virus will be isolated or propagated. However, inactivation of the virus can enable safe handling at a reduced biosafety level, making samples accessible to a diverse array of institutions and investigators. Institutions of all types have an immediate need for guidelines that outline safe collection, handling, and inactivation of samples suspected to contain active virus. Here we provide a practical guide for physicians and researchers wishing to work with materials from patients who are COVID-19 positive or suspected positive. (c) 2020 Wiley Periodicals LLC. Basic Protocol 1: Practical guidelines for the safe collection and handling of specimens collected from COVID-19 and suspected COVID-19 patients Basic Protocol 2: Inactivating SARS-CoV-2."],"journal":"Curr Protoc Cytom","authors":["Bain, William","Lee, Janet S","Watson, Alan M","Stitt-Fischer, Molly S"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502333","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cpcy.77","keywords":["covid-19","sars-cov-2","plaque assay","safety"],"topics":["Prevention"],"weight":1,"_version_":1668890966303440897,"score":132.1622}]}